Meropenem

CHEMBL127 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
383.5 g/mol
LogP
-2.4
Phase
4

A broad-spectrum carbapenem antibiotic given by injection to treat serious and life-threatening bacterial infections, including pneumonia, meningitis, and abdominal and skin infections. It is typically reserved for infections caused by bacteria resistant to other antibiotics.

Molecular Weight

383.5000 g/mol

LogP

-2.40

TPSA

135.00 Ų

Lipinski RO5

Pass

Therapeutic Areas

Mechanism of Action

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12

InChI

InChI=1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1

Molecular Formula

C17H25N3O5S

HBD / HBA

3 / 7

Rotatable Bonds

5

Heavy Atoms

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A broad-spectrum carbapenem antibiotic given by injection to treat serious and life-threatening bacterial infections, including pneumonia, meningitis, and abdominal and skin infections. It is typically reserved for infections caused by bacteria resistant to other antibiotics.

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Yes, Meropenem is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL127. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 441130. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.